Study analysis · PNAS Nexus · 2026
Tirzepatide beats semaglutide at weight loss… and causes fewer side effects? Here’s what the data really says.
People taking tirzepatide lost more weight, faster, and felt better than those taking semaglutide — but only if they were white or female.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at what happened to people who were already taking one of two weight-loss drugs in real life. It found that people on tirzepatide tended to lose more weight than those on semaglutide, but it didn’t randomly assign people to the drugs — so we can’t be sure the drug itself caused the difference.
What’s the bottom line?
This study looked at real patients using two popular weight-loss drugs to see which one helped people lose more weight and feel better.
How strong is this study?
The researchers did a good job matching people who took each drug so they were similar in age, weight, and health — like pairing up kids with similar shoes and backpacks before a race. But they couldn’t control everything, like how well people stuck to their medicine, so we still have to be careful trusting the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=20678)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization; despite propensity matching, unmeasured confounders (e.g., adherence, dose escalation, socioeconomic factors) may influence outcomes, preventing definitive causal inference.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The analysis used de-identified EHR data via a third-party platform with no indication of industry funding or author financial ties.
Independent Analysis Safeguards
- Data de-identification performed per HIPAA Privacy Rule
- Propensity score matching to control for baseline confounders
- AI-enabled curation validated with prior F1 scores
- Analysis conducted in secure data environments without IRB oversight
The study relies on de-identified EHR data from academic medical centers via nference, a third-party analytics platform. No authors, affiliations, or funding sources are disclosed. While the absence of a COI statement is notable, there is no evidence of industry funding or author conflicts. The use of a proprietary platform raises potential data access concerns, but no direct industry involvement is indicated.
Key takeaways
- 01
Tirzepatide users lost 14.7% of their body weight on average vs.
- 02
10.8% for semaglutide users.
- 03
Twice as many people lost 15% or more with tirzepatide (42.6% vs.
- 04
21.6%).
- 05
Tirzepatide also caused fewer side effects like nausea and headaches.
- 06
Losing 15% or more of body weight can significantly improve health conditions like diabetes and high blood pressure — so tirzepatide’s higher success rate and fewer side effects could mean better real-world outcomes.
Surprising findings
- Tirzepatide users had fewer gastrointestinal side effects despite losing more weight — a counterintuitive result.Common belief: More potent weight loss = more nausea and vomiting. But tirzepatide broke that pattern, suggesting its dual GLP-1/GIP mechanism may be better tolerated.
- Race and gender disparities in response were identical for both drugs — meaning the problem isn’t one drug, but something deeper.People assume one drug works better for certain groups — but if both drugs show the same racial/gender gap, the issue likely lies in access, biology, or social determinants, not the medication.
Practical takeaways
If you're considering a GLP-1 drug for weight loss, ask your doctor about tirzepatide — especially if you’ve had bad side effects with semaglutide.
This study didn’t track actual doses or adherence, so results may reflect prescribing patterns, not just drug biology. Also, tirzepatide is more expensive and harder to access.
medium confidenceIf you’re a healthcare provider, track your patients’ weight loss by race and gender — you might be unintentionally leaving some behind.
This study used EHR data from academic centers — results may not reflect rural or underinsured populations.
low confidenceWhy this study matters
Tirzepatide Wins the Weight Loss Race
In a real-world study of over 20,000 obese adults, tirzepatide users lost an average of 14.7% of their body weight over two years — compared to just 10.8% for semaglutide users. Nearly half (42.6%) of tirzepatide users lost 15% or more, nearly double the rate of semaglutide users (21.6%).
This isn’t just a lab result — it’s what’s happening in clinics right now. For people struggling with obesity, this could mean the difference between reversing diabetes or not.
Fewer Side Effects? Yes, Really
Despite losing more weight, tirzepatide users reported significantly lower rates of nausea (27.2% vs 31.4%), vomiting (12.8% vs 17.1%), headaches (23.5% vs 28.4%), and fatigue (26.1% vs 29.7%) than semaglutide users — even among those who lost the most weight.
Everyone assumes more weight loss means more side effects — but this study flips that. It suggests tirzepatide’s dual-action mechanism might be gentler on the body.
The Stark Racial and Gender Divide
White patients made up 91.2% of high responders (≥15% weight loss) for both drugs, while Black and Hispanic patients were overrepresented among minimal responders. Women were 75–80% of high responders, regardless of drug.
This isn’t about the drugs — it’s about systemic gaps in healthcare. If these drugs work better for white women, who’s being left behind? And why?
It’s Not Just the Drug — It’s the Dose
The study couldn’t track actual dose escalation — meaning patients on tirzepatide might’ve been prescribed higher doses or stayed on treatment longer, which could explain better outcomes.
The real winner might not be tirzepatide itself — but access, adherence, and how doctors prescribe it. This changes the conversation from 'which drug?' to 'who gets the best care?'
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at real patients using two popular weight-loss drugs to see which one helped people lose more weight and feel better.
Research results
Tirzepatide users lost 14.7% of their body weight on average vs. 10.8% for semaglutide users. Twice as many people lost 15% or more with tirzepatide (42.6% vs. 21.6%). Tirzepatide also caused fewer side effects like nausea and headaches.
What this means - more context
Losing 15% or more of body weight can significantly improve health conditions like diabetes and high blood pressure — so tirzepatide’s higher success rate and fewer side effects could mean better real-world outcomes.
This study compares real-world weight-loss outcomes and adverse events between tirzepatide and semaglutide in obese adults.
In a propensity-matched cohort of over 20,000 obese adults, tirzepatide was associated with significantly greater (14.7% vs. 10.8%) and faster weight loss than semaglutide, along with lower rates of gastrointestinal and systemic adverse events. Women and White patients were disproportionately represented among high responders, while Black and Hispanic patients were more common among minimal responders.
Methods Used
Retrospective cohort study using de-identified EHR data from U.S. academic medical centers; 1:1 propensity score matching on age, sex, diabetes status, baseline BMI/weight, index year, and follow-up duration; AI-enabled extraction of adverse events from clinical notes; 2-year follow-up.
Main Finding
Tirzepatide was associated with a 14.7% mean 2-year weight loss versus 10.8% for semaglutide (P < 0.001), with nearly double the proportion achieving ≥15% loss (42.6% vs. 21.6%), faster monthly weight loss (2.54% vs. 2.18%), and lower prevalence of nausea, vomiting, constipation, diarrhea, dyspepsia, fatigue, and headache.
Confidence Level
Moderate; strong methodology with propensity matching and AI-enhanced adverse event detection, but observational design limits causal inference and leaves unmeasured confounders (e.g., adherence, dose escalation, social determinants) unaddressed.
Study Flags
Red Flags
- •Retrospective design with potential unmeasured confounders (e.g., adherence, dose escalation)
- •Race/ethnicity not adjusted for in matching despite strong disparities in outcomes
- •Adverse events derived from clinical notes, subject to documentation bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Tirzepatide users had fewer gastrointestinal side effects despite losing more weight — a counterintuitive result.
Common belief: More potent weight loss = more nausea and vomiting. But tirzepatide broke that pattern, suggesting its dual GLP-1/GIP mechanism may be better tolerated.
Practical Takeaways
If you're considering a GLP-1 drug for weight loss, ask your doctor about tirzepatide — especially if you’ve had bad side effects with semaglutide.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at what happened to people who were already taking one of two weight-loss drugs in real life. It found that people on tirzepatide tended to lose more weight than those on semaglutide, but it didn’t randomly assign people to the drugs — so we can’t be sure the drug itself caused the difference.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=20,678)
- 1:1 propensity score matching on multiple key covariates (age, sex, BMI, diabetes status, etc.)
- Use of validated AI-enabled text mining for adverse event extraction
Weaknesses
- Retrospective design with potential for selection and measurement bias
- No randomization — residual confounding likely despite matching
- Unmeasured confounders: adherence, dose escalation, concomitant medications, socioeconomic factors
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at real patients using two popular weight-loss drugs to see which one helped people lose more weight and feel better.
Research results
Tirzepatide users lost 14.7% of their body weight on average vs. 10.8% for semaglutide users. Twice as many people lost 15% or more with tirzepatide (42.6% vs. 21.6%). Tirzepatide also caused fewer side effects like nausea and headaches.
What this means - more context
Losing 15% or more of body weight can significantly improve health conditions like diabetes and high blood pressure — so tirzepatide’s higher success rate and fewer side effects could mean better real-world outcomes.
This study compares real-world weight-loss outcomes and adverse events between tirzepatide and semaglutide in obese adults.
In a propensity-matched cohort of over 20,000 obese adults, tirzepatide was associated with significantly greater (14.7% vs. 10.8%) and faster weight loss than semaglutide, along with lower rates of gastrointestinal and systemic adverse events. Women and White patients were disproportionately represented among high responders, while Black and Hispanic patients were more common among minimal responders.
Methods Used
Retrospective cohort study using de-identified EHR data from U.S. academic medical centers; 1:1 propensity score matching on age, sex, diabetes status, baseline BMI/weight, index year, and follow-up duration; AI-enabled extraction of adverse events from clinical notes; 2-year follow-up.
Main Finding
Tirzepatide was associated with a 14.7% mean 2-year weight loss versus 10.8% for semaglutide (P < 0.001), with nearly double the proportion achieving ≥15% loss (42.6% vs. 21.6%), faster monthly weight loss (2.54% vs. 2.18%), and lower prevalence of nausea, vomiting, constipation, diarrhea, dyspepsia, fatigue, and headache.
Confidence Level
Moderate; strong methodology with propensity matching and AI-enhanced adverse event detection, but observational design limits causal inference and leaves unmeasured confounders (e.g., adherence, dose escalation, social determinants) unaddressed.
Study Flags
Red Flags
- •Retrospective design with potential unmeasured confounders (e.g., adherence, dose escalation)
- •Race/ethnicity not adjusted for in matching despite strong disparities in outcomes
- •Adverse events derived from clinical notes, subject to documentation bias
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Tirzepatide users had fewer gastrointestinal side effects despite losing more weight — a counterintuitive result.
Common belief: More potent weight loss = more nausea and vomiting. But tirzepatide broke that pattern, suggesting its dual GLP-1/GIP mechanism may be better tolerated.
Practical Takeaways
If you're considering a GLP-1 drug for weight loss, ask your doctor about tirzepatide — especially if you’ve had bad side effects with semaglutide.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at what happened to people who were already taking one of two weight-loss drugs in real life. It found that people on tirzepatide tended to lose more weight than those on semaglutide, but it didn’t randomly assign people to the drugs — so we can’t be sure the drug itself caused the difference.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large sample size (n=20,678)
- 1:1 propensity score matching on multiple key covariates (age, sex, BMI, diabetes status, etc.)
- Use of validated AI-enabled text mining for adverse event extraction
Weaknesses
- Retrospective design with potential for selection and measurement bias
- No randomization — residual confounding likely despite matching
- Unmeasured confounders: adherence, dose escalation, concomitant medications, socioeconomic factors
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did a good job matching people who took each drug so they were similar in age, weight, and health — like pairing up kids with similar shoes and backpacks before a race. But they couldn’t control everything, like how well people stuck to their medicine, so we still have to be careful trusting the results.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=20678)+20/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 559 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization; despite propensity matching, unmeasured confounders (e.g., adherence, dose escalation, socioeconomic factors) may influence outcomes, preventing definitive causal inference.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text. The analysis used de-identified EHR data via a third-party platform with no indication of industry funding or author financial ties.
Independent Analysis Safeguards
- Data de-identification performed per HIPAA Privacy Rule
- Propensity score matching to control for baseline confounders
- AI-enabled curation validated with prior F1 scores
- Analysis conducted in secure data environments without IRB oversight
The study relies on de-identified EHR data from academic medical centers via nference, a third-party analytics platform. No authors, affiliations, or funding sources are disclosed. While the absence of a COI statement is notable, there is no evidence of industry funding or author conflicts. The use of a proprietary platform raises potential data access concerns, but no direct industry involvement is indicated.